Seaport Therapeutics has priced its IPO at $18 per share, aiming to raise $254.9 million to further its neuropsychiatric drug development. With shares starting to trade on May 1, 2026, this funding is pivotal for advancing their innovative therapies targeting mental health disorders.
Seaport Therapeutics is targeting a valuation of $912 million in an upcoming IPO, aiming to capitalize on investor interest for future growth. A successful offering could drive market dynamics, potentially impacting other biotech stocks and SPTX's investor interest.
